{
  "id": "mhgap#risk_safety_a87b2448",
  "content": "(namely amitriptyline) were significantly better than y Consider increased risk of bleeding associated\npill placebo in reducing depressive symptoms. with SSRIs, particularly for older people or people\ny The certainties of evidence for change in depressive taking other medicines that can damage the\nsymptoms, response, all-cause dropout, and gastrointestinal mucosa or interfere with clotting\ndropout due to adverse events were low for (e.g. NSAIDs).\ncitalopram, escitalopram, fluoxetine, fluvoxamine,\nResearch gaps\nparoxetine and sertraline (all SSRIs) and for\ny Most of the evidence is from HICs. Further research is\namitriptyline (TCA).\nneeded in LMICs.\ny Amitriptyline and fluoxetine are included in the WHO\ny There was no direct evidence to evaluate the risk of\nEML, with other SSRIs listed as alternatives (13).\nsuicide-related adverse effects of antidepressants.\nRemarks\nImplementation considerations\ny The term “depression” refers to moderate to severe\ny Service providers should only consider\ndepressive episode or disorder.\nantidepressant medicine alone for adults with\ny There were no studies identified in the review that\ndepression when psychological interventions are\nincluded comparisons by severity of depression\nnot available.\n(e.g. moderate versus severe). However, there\ny Service providers should assess psychosocial\nwas no evidence of an association between",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "high",
    "topics": [
      "risk_safety",
      "screening_cues",
      "referral",
      "management"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General — Risk Safety (namely amitriptyline) were significantly better than y Consider increased risk of bleeding associated\npill placebo in reducing depressive symptoms. with SSRIs, particularly for older people or people\ny The certainties of evidence for change in depressive taking other medicines that can damage the\nsymptoms, response, all-cause dropout, and gastrointestinal mucosa or interfere with clotting\ndropout due to adverse events were low for (e.g. NSAIDs).\ncitalopram, escitalopram, fluoxetine, fluvoxamine,\nResearch gaps\nparoxetine and sertraline (all SSRIs) and for\ny Most of the evidence is from HICs. Further research is\namitriptyline (TCA).\nneeded in LMICs.\ny Amitriptyline and fluoxetine are included in the WHO\ny There was no direct evidence to evaluate the risk of\nEML, with other SSRIs listed as alternatives (13).\nsuicide-related adverse effects of antidepressants.\nRemarks\nImplementation considerations\ny The term “depression” refers to moderate to severe\ny Service providers should only consider\ndepressive episode or disorder.\nantidepressant medicine alone for adults with\ny There were no studies identified in the review that\ndepression when psychological interventions are\nincluded comparisons by severity of depression\nnot available.\n(e.g. moderate versus severe). However, there\ny Service providers should assess psychosocial\nwas no evidence of an association between (namely amitriptyline) were significantly better than y consider increased nguy cơ of bleeding associated\npill placebo in reducing depressive symptoms. with ssris, particularly for older people or people\ny the certaintie..."
}